Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denali: NCX 470 vs Latanoprost in Glaucoma/OHT
NCT04630808Phase 3Completed
- Sponsor
- Nicox S.A.
- Start
- Nov 2020
- Primary completion
- Apr 2025
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of bimatoprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Nicox S.A. Primary endpoint: Change from baseline in intraocular pressure at 3 months. Started Nov 2020; status: completed.
02
Drugs
bimatoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT04630808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04630808.